Do Not Increase Vyvanse Above 70 mg in This 49-Year-Old Adult
The maximum FDA-approved dose of Vyvanse (lisdexamfetamine) is 70 mg daily for ADHD in adults, and this patient is already at that ceiling dose—no further increase should be made 1.
Why 70 mg is the Hard Stop
The FDA label explicitly states that 70 mg is the maximum approved daily dose for ADHD treatment in adults ages 18-55 1. This limit is based on controlled clinical trials that demonstrated:
- Efficacy plateau: While dose-response studies show incremental improvements from 30 mg to 70 mg, there is no evidence supporting efficacy or safety beyond 70 mg for ADHD 2
- Safety concerns: Higher doses tested in research settings (up to 250 mg in specialized populations) showed increased cardiovascular effects and adverse events without established benefit for ADHD 3
The 2024 Asian ADHD guidelines confirm this 70 mg maximum across multiple countries 4, and older practice parameters for stimulants emphasize that "if the top recommended dose does not help, more is not necessarily better" 5.
What to Do Instead of Increasing the Dose
When a patient on maximum-dose Vyvanse requests higher doses, follow this algorithm:
1. Reassess Treatment Response Objectively
- Use standardized rating scales (ADHD-RS) to quantify current symptom control
- Distinguish between residual ADHD symptoms versus other issues (anxiety, depression, sleep deprivation, substance use)
- Evaluate whether symptoms occur throughout the day or only at specific times (may indicate duration of action issue rather than dose issue)
2. Optimize Current Regimen Before Changing
- Timing: Ensure medication is taken consistently in the morning with food
- Duration of action: If symptoms emerge late afternoon/evening, this is a coverage gap, not a dose problem—consider adjunctive short-acting stimulant for late-day coverage rather than increasing LDX
- Adherence: Verify consistent daily use (prodrug properties mean LDX doesn't work if not taken regularly)
3. Address Comorbidities and Confounders
- Screen for untreated depression, anxiety, sleep disorders, or substance use that may masquerade as inadequate ADHD control
- Evaluate for medication tolerance (though less common with LDX than immediate-release stimulants)
- Consider whether patient is seeking stimulant effects beyond therapeutic ADHD treatment
4. Switch Medications if Truly Inadequate Response
The evidence-based next step is switching to an alternative medication class, not exceeding maximum dose 5:
- Alternative stimulant: Switch to methylphenidate formulations (different mechanism may provide better response in ~20% of non-responders) 5
- Non-stimulant options: Atomoxetine, guanfacine, or bupropion as monotherapy or augmentation
- Combination therapy: Add non-stimulant to current LDX rather than increasing LDX dose
5. Augment with Non-Pharmacological Interventions
- Cognitive behavioral therapy for ADHD
- Organizational skills training
- Sleep hygiene optimization
- Exercise and lifestyle modifications
Critical Safety Considerations
Common pitfall: Patients may report "tolerance" or request higher doses due to:
- Seeking euphoric effects rather than therapeutic benefit (LDX has lower abuse potential than immediate-release amphetamines but is still a Schedule II controlled substance) 6
- Unrealistic expectations about complete symptom elimination
- Medication diversion (providing to others)
Cardiovascular monitoring: At 70 mg, this patient should already have quarterly blood pressure and pulse checks 5. Increasing beyond approved doses would substantially increase cardiovascular risk without evidence of benefit.
The Bottom Line
Document clearly in the medical record why you are not increasing the dose: patient is at FDA maximum, lack of evidence for higher doses, and outline the alternative management plan described above. If the patient continues to request dose escalation despite optimization attempts, consider:
- Referral to ADHD specialist for second opinion
- Reassessment of diagnosis (is this truly ADHD or another condition?)
- Evaluation for substance use disorder if concerning patterns emerge
The research showing doses up to 250 mg 3 was conducted in highly controlled settings with schizophrenia patients on antipsychotics—this is not applicable to routine ADHD management and should not guide clinical practice for this patient 2.